Advancing Drug Delivery with Silicon Nanoparticles
Nacamed AS is a pharmaceutical company specializing in the development of innovative silicon-based nanoparticles designed to enhance drug delivery systems. Our proprietary technology focuses on creating tailor-made, porous silicon nanoparticles that improve the efficacy and safety of various therapeutic agents
Our platform currently supports partners in:
Drug delivery challenges
Controlling in vivo hydrogen release
The technology behind
The Nacamed technology is based on a new and unique type of nanoparticles that can advance the delivery of medicines. The aim is to maximize medical effects while minimizing side-effects by using our cutting-edge silicon-based drug delivery platform, suitable for several therapy areas and administration routes. This is done by controlling the delivery of small molecules as well as biopharmaceutics.
The advantages of our technology include precise control of the particle synthesis using a unique bottom-up technology with various control parameters. This allows production of particles with the desired properties for the application on interest.
Why work with us
When collaborating with Nacamed, you can start with a simple, initial feasibility study and progress to a full development program for a new product.
With the Nacamed platform you can:
Create new product opportunities
Administer difficult-to-administer products
Extend and manage life-cycle of existing products
Differentiate from competitors
Obtain additional IPR for low-IPR products
Partners and collaborations
Nacamed is always looking for new academic collaborations; principally within in vitro and in vivo studies in established models.
Nacamed is also interested in commercial collaborations with other pharmaceutical companies including potential new drug candidates and super generic drug products.
Meet the Team
-
Dr. Marie Johnsen
Research Scientist
MSc in Nanotechnology, Industrial PhD
Master's degree from the Nanotechnology engineering program at NTNU. PhD from the Department of Pharmacy at UiO. Research experience from IFE, SINTEF and UCSD.
-
Dr. Jo Klaveness
CSO
M. Sci (c.real.), M.Sci Pharm (c.pharm), Ph.D (dr.scient), professor em.
Extensive experience from pharmaceutical industry (incl. VP in R&D, Nycomed), inventor of appr. 150 patent families (125 issued US patents) covering several commercial products.
-
Nils Lemming
CEO
Executive MBA in Management Control
IB from UWC in Canada B.sc. Econ from CBS in Copenhagen. Executive MBA in Management Control from NHH, Bergen (2014). 35 years top management experience in the service industry.
-
Robert Storli
Research Scientist
MSc in Chemistry
Master’s degree in organic chemistry from the University of Bergen with experience from pharmaceutical industry (GE Healthcare).